Hypothalamic Pharmacology · Module 3 of 4

Growth Hormone Axis Pharmacology

Somatostatin analogs, GH replacement, secretagogues, and pegvisomant

IGF-1 is the pharmacodynamic monitoring marker for both GH excess and deficiency because it reflects integrated 24-hour GH secretion far more reliably than any single GH measurement — acromegaly diagnosis requires failure to suppress GH below 1 ng/mL (or <0.4 ng/mL by ultrasensitive assay) on a 75 g OGTT combined with elevated age- and sex-adjusted IGF-1, while treatment targets normalized age- and sex-adjusted IGF-1 regardless of which agent is used.
Pasireotide's metabolic liability follows directly from its receptor profile — SSTR5 affinity 40-fold greater than octreotide suppresses insulin secretion and incretin (GLP-1 and GIP) release simultaneously; DPP-4 inhibitors are ineffective because they depend on intact incretin responses that pasireotide has already blocked at their source; metformin has limited utility; GLP-1 receptor agonists and insulin are the preferred agents for pasireotide-induced hyperglycemia, which occurs in 57–73% of patients.
Pegvisomant monitoring is IGF-1 only — never GH; GH rises during pegvisomant therapy because IGF-1 suppression removes negative pituitary feedback, and a rising GH on pegvisomant does not indicate treatment failure; annual pituitary MRI is required because pegvisomant does not reduce tumor volume, unlike somatostatin analogs which can shrink tumors 20–50%.
Somatropin induces CYP3A4 and CYP2C19, accelerating glucocorticoid clearance — this can unmask previously subclinical central adrenal insufficiency in panhypopituitary patients or render an existing hydrocortisone replacement dose inadequate; HPA axis status must be confirmed and glucocorticoid replacement adjusted upward 20–30% if needed before and after initiating growth hormone replacement; somatropin also accelerates cyclosporine clearance via CYP3A4 induction, risking rejection in transplant patients.
Macimorelin (oral GHSR-1a agonist) is the practical alternative to the insulin tolerance test for adult GH deficiency diagnosis — single oral dose 0.5 mg/kg, peak GH <2.8 ng/mL at 30/45/60/90 minutes confirms deficiency; strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) reduce macimorelin exposure and can produce false-positive diagnoses and must be stopped before testing; QTc prolongation risk requires baseline ECG.

Abbreviations: GH = growth hormone · IGF-1 = insulin-like growth factor-1 · GHRH = growth hormone-releasing hormone · SSA = somatostatin analog · SSTR = somatostatin receptor subtype · GHSR = growth hormone secretagogue receptor · PLGA = poly(lactic-co-glycolic acid) · LAR = long-acting release · DPP-4 = dipeptidyl peptidase-4 · GLP-1 = glucagon-like peptide-1 · HPA = hypothalamic-pituitary-adrenal · OGTT = oral glucose tolerance test · LFT = liver function test · MRI = magnetic resonance imaging · PEG = polyethylene glycol · JAK2 = Janus kinase 2

GH Axis Drug Classes at a Glance

Drug Class	Prototype(s)	Mechanism	Primary Use	Monitor
SSTR2/5 SSA	Octreotide LAR, Lanreotide Autogel	Gi-coupled SSTR2/5 activation ↓ GH and IGF-1	Acromegaly (first-line after surgery); carcinoid; VIPoma	GH + IGF-1; glucose; gallstones (q6–12 months US)
Pan-SSTR agonist	Pasireotide LAR	SSTR1/2/3/5 — SSTR5 affinity 40× octreotide	SSA-resistant acromegaly; Cushing disease	GH + IGF-1; glucose at 1–3 months then q6 months; HbA1c
GHRH analog	Tesamorelin	GHRH-R Gs activation → endogenous GH release	HIV-associated lipodystrophy (visceral fat)	IGF-1; glucose; contraindicated in active malignancy
GHSR agonist (oral)	Macimorelin	Ghrelin receptor (GHSR-1a) → GH pulse	Diagnosis of adult GH deficiency (single-dose test)	Peak GH at 30/45/60/90 min; baseline ECG; avoid CYP3A4 inducers
GH replacement	Somatropin	Recombinant GH → hepatic IGF-1 production	Adult GH deficiency; pediatric growth failure	IGF-1; fasting glucose; DEXA; HPA axis before starting
GH receptor antagonist	Pegvisomant	Blocks GH receptor dimerization → ↓ IGF-1 (JAK2/STAT5 not activated)	Acromegaly — especially SSA-resistant	IGF-1 ONLY (not GH); LFTs q6 months; pituitary MRI annually

Somatostatin Analogs — Formulation and Key Differences

Octreotide LAR — PLGA Microsphere IM

20–40 mg Every 28 Days

20, 30, 40 mg IM every 28 days
Bridge with SC octreotide for ~14 days after first LAR injection while depot levels establish
SSTR2/5-selective; GH normalization ~50–60%; IGF-1 normalization ~30–50%
Hyperglycemia 10–20%; cholelithiasis 20–30% long-term
Also used: carcinoid syndrome, VIPoma, variceal hemorrhage

Lanreotide Autogel — Deep SC Self-Assembling Gel

60–120 mg Every 4 Weeks (or Extended)

60, 90, 120 mg deep SC every 4 weeks
No 14-day bridge required — immediate therapeutic levels from gel depot
Extended intervals (every 6–8 weeks) for patients with stable biochemical control
SSTR2/5-selective; comparable efficacy to octreotide LAR
Fecal elimination (<5% renal) — no dose adjustment in renal impairment

Pasireotide LAR — Pan-SSTR agonist

40–60 mg Every 28 Days — Second-Line

40 or 60 mg IM every 28 days
PAOLA trial: biochemical control in 31–38% of SSA-resistant patients (vs. 19% switching first-generation agent)
Cushing disease: corticotroph adenomas express SSTR5 > SSTR2
Hyperglycemia 57–73% — prefer GLP-1 receptor agonist or insulin
DPP-4 inhibitors and metformin largely ineffective (incretin source suppressed)

Pegvisomant and Somatropin — Key Distinctions

Pegvisomant (Somavert) — GH Receptor Antagonist

IGF-1 Normalization in 90–97%; No Tumor Shrinkage

PEGylated GH analog — blocks receptor dimerization, prevents JAK2/STAT5 signaling
t½ ~6 days; once-daily or every-other-day SC; starting dose 40–80 mg daily
IGF-1 normalization in 90–97% — highest of any acromegaly drug class
GH rises during therapy (loss of IGF-1 feedback) — do NOT monitor GH; IGF-1 only
Does not reduce tumor volume — pituitary MRI annually required
Hepatotoxicity: LFTs at baseline and every 6 months; stop if ALT/AST >5× ULN
SSA + pegvisomant combination: superior IGF-1 control when IGF-1 alone remains elevated on SSA

Somatropin — CYP3A4 Induction Consequences

GH Replacement: Two High-Yield Drug Interactions

Induces CYP3A4 and CYP2C19 → accelerates glucocorticoid clearance
May unmask central adrenal insufficiency in panhypopituitary patients — assess HPA axis before starting; increase hydrocortisone 20–30% if needed
Reduces cyclosporine levels via CYP3A4 induction → risk of rejection in transplant patients; monitor levels
Women on oral (not transdermal) estrogen require higher somatropin doses — first-pass hepatic metabolism reduces GH receptor signaling
Adverse effects: fluid retention, carpal tunnel, arthralgias (dose-dependent); glucose intolerance
Contraindicated in active malignancy and acute critical illness

Acromegaly Treatment Algorithm — Step-by-Step

Step 1 — Surgery: Transsphenoidal resection is first-line for all resectable tumors. Biochemical cure criteria: random GH below 1 ng/mL (or <0.4 ng/mL nadir on OGTT) and normalized age- and sex-adjusted IGF-1. Medical therapy is used for residual or recurrent disease and pre-surgical tumor debulking.

Step 2 — First-generation SSA: Octreotide LAR or lanreotide Autogel, uptitrated to maximum dose over 6–12 months. Target: random GH <1 ng/mL and normal IGF-1. Cholelithiasis surveillance by ultrasound every 6–12 months.

Step 3 — Inadequate SSA control — three options: (a) Switch to pasireotide LAR if both GH and IGF-1 remain elevated and hyperglycemia risk is acceptable; (b) Add pegvisomant to SSA when IGF-1 alone remains elevated — highest combined biochemical control rates; (c) Add cabergoline to SSA if prolactin is co-elevated, suggesting a D2R-expressing co-secreting tumor (cabergoline monotherapy achieves IGF-1 normalization in ~10–15% of acromegaly patients).

Step 4 — Pegvisomant monotherapy: for patients intolerant of or unresponsive to SSA; monitor IGF-1 only (not GH); annual pituitary MRI; LFTs every 6 months. Radiotherapy reserved for aggressive or multi-drug-refractory tumors — GH and IGF-1 effects may take years to manifest.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 40: Estrogens, Progestins, and the Female Reproductive Tract	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 44: Estrogens and Progestins	McGraw-Hill; 2023
Giustina A, Veldhuis JD.	Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human	Endocr Rev. 1998;19(6):717–797
Patel YC.	Somatostatin and its receptor family	Front Neuroendocrinol. 1999;20(3):157–198
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K.	Ghrelin is a growth-hormone-releasing acylated peptide from stomach	Nature. 1999;402(6762):656–660
Melmed S.	Acromegaly pathogenesis and treatment	J Clin Invest. 2009;119(11):3189–3202
Freda PU.	Somatostatin analogs in acromegaly	J Clin Endocrinol Metab. 2002;87(7):3013–3018
Gadelha MR, Bronstein MD, Brue T, et al; PAOLA study investigators.	Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial	Lancet Diabetes Endocrinol. 2014;2(11):875–884
Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S.	Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers	J Clin Endocrinol Metab. 2013;98(8):3446–3453
Falutz J, Allas S, Blot K, et al.	Metabolic effects of a growth hormone-releasing factor in patients with HIV	N Engl J Med. 2007;357(23):2359–2370
Yuen KCJ, Biller BMK, Radovick S, et al.	American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care	Endocr Pract. 2019;25(Suppl 2):1–44
Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society.	Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline	J Clin Endocrinol Metab. 2011;96(6):1587–1609
Trainer PJ, Drake WM, Katznelson L, et al.	Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant	N Engl J Med. 2000;342(16):1171–1177
van der Lely AJ, Hutson RK, Trainer PJ, et al.	Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist	Lancet. 2001;358(9295):1754–1759
Giustina A, Chanson P, Bronstein MD, et al; Acromegaly Consensus Group.	A consensus on criteria for cure of acromegaly	J Clin Endocrinol Metab. 2010;95(7):3141–3148
Abs R, Verhelst J, Maiter D, et al.	Cabergoline in the treatment of acromegaly: a study in 64 patients	J Clin Endocrinol Metab. 1998;83(2):374–378